[DOI] [PubMed] [Google Scholar] 62.Schaakxs D., Kalbermatten D.F., Raffoul W., Wiberg M., Kingham P.J
Studies suggest this approach can achieve tissue concentrations approaching injectable levels
As T2D is often associated with having a high body mass index, one would be forgiven for assuming that the needs of people who use GLP-1s for weight loss and those using it to treat diabetes would be very similar, but recent market research suggests a number of significant differences:5 The majority of people using GLP-1s for weight loss are in their 30s to 50s (often as part of a wider strategy to be proactive about their health), whereas those using GLP-1s for diabetes control are more likely to be over 60
[DOI] [PMC free article] [PubMed] [Google Scholar] 185.Kroenke K., Spitzer R.L., Williams J.B., Lowe B
Delightful natural citrus flavor and scent
The Federal Bureau of Investigation also recently warned the public about safety concerns related to fraudulent compounding practices associated with weight loss drugs, warning that "[s]ome healthcare providers are using compounded mixtures of unknown drugs that do not contain semaglutide, drugs with high levels of impurities, and unsafe or unapproved drugs." Novo Nordisk is continuing to actively address this issue through education, advocacy, and legal action, fighting on behalf of patients who deserve to know what they are injecting into their body
